Patient Preference for Treatment of Moderate-To-Severe Psoriasis in Japan
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Psoriasis
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 232
- Locations
- 1
- Primary Endpoint
- Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of moderate-to-severe Psoriasis (PsO) by physician (phase 1) or self-reported (phase 2)
- •Currently taking systemic psoriasis treatment
- •Japanese resident aged 20 years and older
Exclusion Criteria
- •Unable or unwilling to provide informed consent
- •Diagnosis of guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis
Outcomes
Primary Outcomes
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height
Time Frame: At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Severity of PsO
Time Frame: At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 1: Sex
Time Frame: At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Residence
Time Frame: At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Weight
Time Frame: At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Type of occupation
Time Frame: At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Education
Time Frame: At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Age
Time Frame: At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Time since PsO diagnosis
Time Frame: At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Time on current PsO treatment
Time Frame: At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Level of income
Time Frame: At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Age
Time Frame: At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Current treatments for PsO
Time Frame: At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Residence
Time Frame: At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Employment status
Time Frame: At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Education
Time Frame: At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Current treatments for PsO
Time Frame: At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Previous treatments for PsO
Time Frame: At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Comorbid conditions of interest
Time Frame: At Baseline
Psoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute
Time Frame: Within 60 minutes of survey/interview
Distribution of clinical characteristics of PsO participants in Phase 1: Total number of previous treatments
Time Frame: At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Sex
Time Frame: At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time since PsO diagnosis
Time Frame: At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Level of income
Time Frame: At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Previous treatments for PsO
Time Frame: At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time on current PsO treatment
Time Frame: At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Employment status
Time Frame: At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Self-reported severity
Time Frame: At Baseline